Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation
Journal of the American Heart Association · 21.10.2025 · 14 (20)
DOI: 10.1161/jaha.125.044102 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the American Heart Association, erschienen am 21.10.2025. Verfasst von Ki Hong Choi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center Sungkyunkwan University School of Me…. Hauptthemen laut MEDLINE: Aortic Aneurysm, Abdominal, Dual Anti-Platelet Therapy, Endovascular Procedures, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The optimal antiplatelet regimen after standard endovascular aneurysm repair (EVAR) in patients without atherosclerotic cardiovascular disease remains uncertain. Clinical guidelines offer limited recommendations, and data specific to this population are sparse. This study aimed to compare the efficacy and safety of single versus dual antiplatelet therapy (DAPT) in patients undergoing standard EVAR for abdominal aortic aneurysms without established atherosclerotic cardiovascular disease.
Methods
This study emulated a target trial using the Korean National Health Insurance Service database, which includes the entire Korean population. We identified all patients who underwent standard EVAR between January 2003 and September 2023 and excluded those with atherosclerotic cardiovascular disease or no antiplatelet therapy. Patients were categorized by discharge medication into single antiplatelet therapy or DAPT groups. The primary cardiovascular efficacy end point was major adverse cardiac and cerebrovascular events (all‐cause death, myocardial infarction, or ischemic stroke). The EVAR‐specific efficacy end point was abdominal aortic aneurysm reintervention or surgery. The safety end point was major or clinically relevant nonmajor bleeding. Inverse probability treatment weighting was applied to adjust baseline differences.
Results
Among 8325 patients, 4162 (50.0%) received single antiplatelet therapy (80.6% aspirin, 19.4% clopidogrel), and 4163 (50.0%) received DAPT (aspirin plus clopidogrel). There were no significant differences between single antiplatelet therapy and DAPT in the risk of major adverse cardiac and cerebrovascular events (inverse probability treatment weighting‐hazard ratio [HR], 1.07 [95% CI, 0.93–1.22]) or abdominal aortic aneurysm reintervention/surgery (inverse probability treatment weighting‐HR, 1.07 [95% CI, 0.92–1.24]). However, DAPT was associated with a higher risk of major or clinically relevant nonmajor bleeding (inverse probability treatment weighting‐HR, 1.20 [95% CI, 1.02–1.41]).
Conclusions
In patients without atherosclerotic cardiovascular disease undergoing standard EVAR, DAPT did not confer cardiovascular or procedural benefit but was associated with increased bleeding. Single antiplatelet therapy may represent a safer and equally effective antiplatelet strategy in this population. Registration URL: https://clinicaltrials.gov ; Unique Identifier: NCT06876727.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Republic of Korea.
- Department of Clinical Research Design and Evaluation, SAIHST Sungkyunkwan University Seoul Republic of Korea.
- Center for Clinical Epidemiology Samsung Medical Center Seoul Republic of Korea.
- Department of Radiology, Korea University Guro Hospital Korea University College of Medicine Seoul Republic of Korea.
ORCID-Profile: Ki Hong Choi, Jihee Nam, Take Kyu Park, Myung Gyu Song, Tae-Seok Seo, Woo Jin Yang, Seung-Hyuk Choi
Zitieren
APA
Choi, K. H., Kang, D., Nam, J., Park, T. K., Song, M. G., Seo, T. S., Yang, W. J., & Choi, S. H. (2025). Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation. Journal of the American Heart Association, 14(20). https://doi.org/10.1161/jaha.125.044102
Vancouver
Choi KH, Kang D, Nam J, Park TK, Song MG, Seo TS, et al. Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation. Journal of the American Heart Association. 2025;14(20). doi:10.1161/jaha.125.044102
BibTeX
@article{Choi2025,
author = {Choi, Ki Hong and Kang, Danbee and Nam, Jihee and Park, Take Kyu and Song, Myung Gyu and Seo, Tae-Seok and Yang, Woo Jin and Choi, Seung-Hyuk},
title = {Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {20},
doi = {10.1161/jaha.125.044102}
}
EUVIMED